SEC Filings

Form S-4
PDS BIOTECHNOLOGY CORP filed this Form S-4 on 12/21/2018
Document Outline
Entire Document (14054.2 KB)
Subdocument 1 - S-4 - S-4
Page 1 - As filed with the U.S. Securities and Exchange Commission on December 20, 2018
Page 2 - The information in this proxy statement/prospectus/information statement is not complete and may be
Page 3 - EDGE THERAPEUTICS, INC.
Page 4 - THE EDGE BOARD HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO
Page 5 - TABLE OF CONTENTS
Page 6 - N/A
Page 7 - RESULTS OF OPERATIONS
Page 8 - N/A
Page 9 - QUESTIONS AND ANSWERS ABOUT THE MERGER
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - PROSPECTUS SUMMARY
Page 17 - Reasons for the Merger
Page 18 - Opinion of the Financial Advisor to the Edge Board
Page 19 - opinion and the related analyses set forth in this proxy statement/prospectus/information statement
Page 20 - Treatment of PDS Stock Options and Warrants
Page 21 - Termination of the Merger Agreement
Page 22 - N/A
Page 23 - Lock-up Agreements
Page 24 - PDS Solicitation of Written Consents
Page 25 - Interests of the PDS Directors and Executive Officers in the Merger
Page 26 - Considerations with Respect to U.S. Federal Income Tax Consequences of the Merger
Page 27 - Regulatory Approvals
Page 28 - Comparison of Stockholder Rights
Page 29 - SELECTED HISTORICAL AND UNAUDITED PRO FORMA
Page 30 - Selected Unaudited Pro Forma Condensed Combined Financial Data of Edge and PDS
Page 31 - Comparative Historical and Unaudited Pro Forma per Share Data
Page 32 - MARKET PRICE AND DIVIDEND INFORMATION
Page 33 - RISK FACTORS
Page 34 - The merger may be completed even though material adverse changes may result from the announcement of
Page 35 - The market price of the combined company s common stock following the merger may decline as a result
Page 36 - Certain provisions of the Merger Agreement may discourage third parties from submitting alternative
Page 37 - Failure to obtain stockholder approval for the proposed reverse stock split may result in the combin
Page 38 - The pendency of the merger could have an adverse effect on the trading price of Edge common stock an
Page 39 - Risks Related to Development and Regulatory Approval
Page 40 - Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and re
Page 41 - Failure to obtain regulatory approval in international jurisdictions would prevent Edge s product ca
Page 42 - Risks Related to Edge s Business and Industry
Page 43 - Edge s employees may engage in misconduct or other improper activities, including noncompliance with
Page 44 - Obtaining and maintaining Edge s patent protection depends on compliance with various procedural, do
Page 45 - Third parties may initiate legal proceedings alleging that Edge is infringing their intellectual pro
Page 46 - Intellectual property disputes could cause Edge to spend substantial resources.
Page 47 - If Edge were to resume research and development activities, Edge will require additional capital to
Page 48 - Market volatility may affect Edge s stock price and the value of Edge s stockholders investment.
Page 49 - Future issuances of Edge s common stock or rights to purchase common stock, including pursuant to Ed
Page 50 - Because Edge does not anticipate paying any cash dividends on Edge s capital stock in the foreseeabl
Page 51 - Edge s disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 52 - PDS has incurred significant losses since its inception and expects to continue to incur significant
Page 53 - PDS s independent auditor has expressed doubt about PDS s ability to continue as a going concern.
Page 54 - Raising additional funds by issuing securities may cause dilution to existing stockholders, and rais
Page 55 - PDS s future success depends on its ability to retain executive officers and attract, retain and mot
Page 56 - PDS will need to expand its organization, and may experience difficulties in managing this growth, w
Page 57 - PDS expects to incur significant additional costs as a result of being a public company, which may a
Page 58 - Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process a
Page 59 - PDS faces significant competition from other biotechnology and pharmaceutical companies, and its ope
Page 60 - PDS0101 may cause adverse effects or have other properties that could delay or prevent their regulat
Page 61 - Even if PDS obtains FDA approval in the United States, it may never obtain approval for or commercia
Page 62 - Even if PDS0101 receive marketing approval, it may fail to achieve market acceptance by physicians,
Page 63 - PDS may expend its limited resources to pursue a particular product candidate or indication and fail
Page 64 - N/A
Page 65 - Product liability lawsuits against PDS could cause it to incur substantial liabilities and could lim
Page 66 - Recently enacted and future legislation may increase the difficulty and cost for PDS to obtain marke
Page 67 - If PDS is unable to establish or manage strategic collaborations in the future, PDS s revenue and dr
Page 68 - PDS s relationships with customers and third-party payors will be subject to applicable anti-kickbac
Page 69 - Risks Related to PDS s Intellectual Property
Page 70 - PDS may be involved in lawsuits to protect or enforce its patents, the patents of its licensors or i
Page 71 - Changes in U.S. patent law could diminish the value of patents in general, thereby impairing PDS s a
Page 72 - Risks Related to the Combined Company
Page 73 - Edge and PDS do not anticipate that the combined company will pay any cash dividends in the foreseea
Page 74 - Because the merger will result in an ownership change under Section 382 of the Code for Edge, pre-me
Page 75 - CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
Page 76 - N/A
Page 77 - THE SPECIAL MEETING OF EDGE STOCKHOLDERS
Page 78 - Voting and Revocation of Proxies
Page 79 - Required Vote
Page 80 - Other Matters
Page 81 - THE MERGER
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - Edge Reasons for the Merger
Page 91 - N/A
Page 92 - PDS Reasons for the Merger
Page 93 - Opinion of the Financial Advisor to the Edge Board
Page 94 - Review of Solicitation Process
Page 95 - Financial Analyses of Edge
Page 96 - Selected Comparable Public Companies Analysis
Page 97 - N/A
Page 98 - Other Information
Page 99 - N/A
Page 100 - Interests of the Edge Directors and Executive Officers in the Merger
Page 101 - Equity Awards and Edge Common Stock
Page 102 - Continued Service
Page 103 - Indemnification and Insurance
Page 104 - Form of the Merger
Page 105 - Effective Time of the Merger
Page 106 - N/A
Page 107 - Tax Consequences if the Merger Failed to Qualify as a Reorganization
Page 108 - Anticipated Accounting Treatment
Page 109 - N/A
Page 110 - N/A
Page 111 - THE MERGER AGREEMENT
Page 112 - N/A
Page 113 - Treatment of Edge Stock Options and Edge RSUs
Page 114 - Directors and Executive Officers of the Combined Company Following the Merger
Page 115 - N/A
Page 116 - Representations and Warranties
Page 117 - Non-Solicitation
Page 118 - N/A
Page 119 - Meetings of Stockholders
Page 120 - N/A
Page 121 - N/A
Page 122 - Other Agreements
Page 123 - Termination of the Merger Agreement
Page 124 - Termination Fees
Page 125 - Amendment
Page 126 - AGREEMENTS RELATED TO THE MERGER
Page 127 - Lock-up Agreements
Page 128 - MATTERS BEING SUBMITTED TO A VOTE OF EDGE STOCKHOLDERS
Page 129 - Edge Proposal No. 2 (the Reverse Stock Split Proposal): Approval of the Amendment to the Certificate
Page 130 - Potential Increased Investor Interest
Page 131 - Criteria to be Used for Determining Whether to Implement the Reverse Stock Split
Page 132 - Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates
Page 133 - Accounting Consequences
Page 134 - N/A
Page 135 - Required Vote; Recommendation of Board of Directors
Page 136 - Edge Proposal No. 3 (the Equity Incentive Plan Proposal): Approval of the Amended and Restated Edge
Page 137 - Basis for Board of Directors Adoption of the Restated Plan
Page 138 - Outstanding Awards; Burn Rate
Page 139 - Summary of Restated Plan
Page 140 - Awards Generally
Page 141 - Change in Control and other Corporate Transactions
Page 142 - Certain Corporate Transactions
Page 143 - Foreign Nationals
Page 144 - N/A
Page 145 - N/A
Page 146 - N/A
Page 147 - THE EDGE BOARD UNANIMOUSLY RECOMMENDS THAT THE EDGE STOCKHOLDERS VOTE FOR THE APPROVAL OF THE AMENDE
Page 148 - EDGE BUSINESS
Page 149 - Intellectual Property
Page 150 - Manufacturing
Page 151 - Government Regulation
Page 152 - Foreign Regulation
Page 153 - Legal Proceedings
Page 154 - PDS BUSINESS
Page 155 - N/A
Page 156 - Versamune - A Next Generation Immunotherapy and Cancer Immunotherapy
Page 157 - PDS Clinical Development Plan
Page 158 - PDS0101 + Keytruda in HPV-positive recurrent or metastatic head and neck cancer
Page 159 - Other Development Programs
Page 160 - Breast cancer: Breast cancer is a leading cause of cancer-related mortality among women worldwide. I
Page 161 - Commercialization of Product Candidates
Page 162 - Versamune Mechanisms of Action (MOA)
Page 163 - Example 1: In-vitro studies performed to examine the ability of Versamune to promote antigen uptake
Page 164 - Figure 4: Versamune enhances protein uptake by dendritic cells
Page 165 - Figure 6: Versamune promotes antigen cross-presentation to killer T-cells (CD8+) in-vitro
Page 166 - Figure 7: Versamune (R-DOTAP) promotes antigen cross presentation in-vivo leading to superior prolif
Page 167 - Figure 8: Versamune (R-DOTAP) administration induces in-vivo lymph node production of Type I interfe
Page 168 - Figure 9: Single subcutaneous injection of PDS0101 leads to sustained and elevated levels of the imp
Page 169 - N/A
Page 170 - Figure 13:
Page 171 - Example 4: Studies to understand the effect of the Versamune -based immunotherapy on the tumor s mic
Page 172 - Figure 14:
Page 173 - Figure 15:
Page 174 - N/A
Page 175 - Example 5: Studies to understand the effect of Versamune -based immunotherapy combined with a checkp
Page 176 - Figure 4: Versamune (R-DOTAP) synergizes with anti-mouse PD1 checkpoint inhibitor treatment to signi
Page 177 - Intellectual Property
Page 178 - Material Agreements
Page 179 - Patent License Agreement with National Institutes of Health.
Page 180 - Government Regulation and Product Approval
Page 181 - N/A
Page 182 - U.S. Review and Approval Processes
Page 183 - Post-Approval Requirements
Page 184 - Other U.S. Healthcare Laws and Compliance Requirements
Page 185 - N/A
Page 186 - Coverage, Pricing and Reimbursement
Page 187 - Foreign Regulation
Page 188 - Legal Proceedings
Page 189 - EDGE MANAGEMENT S DISCUSSION AND ANALYSIS OF
Page 190 - N/A
Page 191 - Key Components of Edge s Statement of Operations
Page 192 - Results of Operations
Page 193 - Comparison of the Years Ended December 31, 2017 and 2016
Page 194 - Hercules Loan and Security Agreement
Page 195 - Net Cash (Used In) Provided by Financing Activities
Page 196 - Contractual Obligations and Commitments
Page 197 - Critical Accounting Polices and Estimates
Page 198 - PDS MANAGEMENT S DISCUSSION AND ANALYSIS OF
Page 199 - PDS s independent auditor has expressed doubt about PDS s ability to continue as a going concern
Page 200 - General and Administrative Expense
Page 201 - General and Administrative
Page 202 - Cash Flows
Page 203 - Cash Flows from Financing Activities
Page 204 - Contractual Obligations and Other Commitments
Page 205 - Income Taxes
Page 206 - N/A
Page 207 - MANAGEMENT FOLLOWING THE MERGER
Page 208 - Brian A. Leuthner
Page 209 - Robert Spiegel, M.D.
Page 210 - Gregory Freitag
Page 211 - Board Committees
Page 212 - Compensation Committee
Page 213 - Nominating and Corporate Governance Committee
Page 214 - Compensation Committee Interlocks and Insider Participation
Page 215 - EDGE EXECUTIVE COMPENSATION
Page 216 - Outstanding Equity Awards at Year-End
Page 217 - N/A
Page 218 - N/A
Page 219 - PDS EXECUTIVE COMPENSATION
Page 220 - Pension Benefits
Page 221 - Employment Benefits Plans
Page 222 - Plan Administration. The PDS Board or a duly authorized committee of its board of directors administ
Page 223 - CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS
Page 224 - Edge Related-Party Transactions Policy
Page 225 - PDS Related-Party Transactions Policy
Page 226 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Page 227 - Unaudited Pro Forma Condensed Combined Balance Sheet
Page 228 - Unaudited Pro Forma Condensed Combined Statement of Operations
Page 229 - Unaudited Pro Forma Condensed Combined Statement of Operations
Page 230 - Notes to the Unaudited Pro Forma Condensed Combined Financial Information
Page 231 - Note 2 Preliminary purchase price allocation
Page 232 - Note 3 Pro forma adjustments
Page 233 - N/A
Page 234 - DESCRIPTION OF EDGE CAPITAL STOCK
Page 235 - Stock Options
Page 236 - Certificate of Incorporation and Bylaws
Page 237 - COMPARISON OF RIGHTS OF HOLDERS OF EDGE STOCK AND PDS STOCK
Page 238 - N/A
Page 239 - N/A
Page 240 - N/A
Page 241 - PRINCIPAL STOCKHOLDERS OF EDGE
Page 242 - N/A
Page 243 - PRINCIPAL STOCKHOLDERS OF PDS
Page 244 - PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY
Page 245 - N/A
Page 246 - LEGAL MATTERS
Page 247 - OTHER MATTERS
Page 248 - INDEX TO FINANCIAL STATEMENTS
Page 249 - Report of Independent Registered Public Accounting Firm
Page 250 - EDGE THERAPEUTICS, INC.
Page 251 - EDGE THERAPEUTICS, INC.
Page 252 - EDGE THERAPEUTICS, INC.
Page 253 - EDGE THERAPEUTICS, INC.
Page 254 - N/A
Page 255 - Edge Therapeutics, Inc.
Page 256 - N/A
Page 257 - N/A
Page 258 - Note 3 - Fair Value of Financial Instruments
Page 259 - Note 7 - Stock Options
Page 260 - N/A
Page 261 - Note 8 - Income Taxes
Page 262 - Note 9 - Commitments and Contingencies
Page 263 - N/A
Page 264 - Note 10 - Debt
Page 265 - Note 11 - Retirement Plan
Page 266 - Note 12 - Selected Quarterly Financial Data (Unaudited)
Page 267 - EDGE THERAPEUTICS, INC.
Page 268 - EDGE THERAPEUTICS, INC.
Page 269 - EDGE THERAPEUTICS, INC.
Page 270 - Edge Therapeutics, Inc.
Page 271 - Note 2 - Summary of Significant Accounting Policies
Page 272 - N/A
Page 273 - Note 3 - Fair Value of Financial Instruments
Page 274 - Note 5 - Accrued Expenses
Page 275 - N/A
Page 276 - Note 7 - Income Taxes
Page 277 - Note 8 - Commitments and Contingencies
Page 278 - N/A
Page 279 - Note 9 - Debt
Page 280 - Note 10 - Retirement Plan
Page 281 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 282 - PDS Biotechnology Corporation
Page 283 - PDS Biotechnology Corporation
Page 284 - PDS Biotechnology Corporation
Page 285 - PDS Biotechnology Corporation
Page 286 - PDS BIOTECHNOLOGY CORPORATION
Page 287 - Cash and Cash Equivalents
Page 288 - Stock-Based Compensation
Page 289 - Revenue Recognition
Page 290 - Concentrations of Credit Risk
Page 291 - N/A
Page 292 - N/A
Page 293 - N/A
Page 294 - N/A
Page 295 - N/A
Page 296 - Common Stock Transactions
Page 297 - Preferred Stock Transactions
Page 298 - N/A
Page 299 - N/A
Page 300 - Operating Leases
Page 301 - Litigation
Page 302 - N/A
Page 303 - N/A
Page 304 - N/A
Page 305 - PDS Biotechnology Corporation
Page 306 - PDS Biotechnology Corporation
Page 307 - PDS Biotechnology Corporation
Page 308 - PDS Biotechnology Corporation
Page 309 - PDS BIOTECHNOLOGY CORPORATION
Page 310 - Use of Estimates
Page 311 - N/A
Page 312 - Common Stock Transactions
Page 313 - Preferred Stock Transactions
Page 314 - N/A
Page 315 - Operating Leases
Page 316 - Litigation
Page 317 - N/A
Page 318 - N/A
Page 319 - N/A
Page 320 - Annex A
Page 321 - TABLE OF CONTENTS
Page 322 - TABLE OF CONTENTS
Page 323 - TABLE OF CONTENTS
Page 324 - TABLE OF CONTENTS
Page 325 - THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this Agreement ) is made and entered into as o
Page 326 - Company Stockholder Written Consents ).
Page 327 - Conversion of Shares.
Page 328 - Closing of the Company s Transfer Books. At the Effective Time: (a) all shares of Company Capital St
Page 329 - Appraisal Rights.
Page 330 - Pro-Forma Capitalization. The anticipated pro-forma capitalization of the Company immediately prior
Page 331 - Vote Required. The affirmative vote (or written consent) of the holders of a majority of the shares
Page 332 - Financial Statements.
Page 333 - Absence of Changes. Except as set forth on Section 2.8 of the Company Disclosure Schedule, between t
Page 334 - Company Real Estate Leases ), each of which is in full force and effect (assuming the due execution
Page 335 - N/A
Page 336 - Agreements, Contracts and Commitments.
Page 337 - Compliance; Permits; Restrictions.
Page 338 - Company Permits ). Section 2.14(b) of the Company Disclosure Schedule identifies each Company Permit
Page 339 - HIPAA ), including the standards for the privacy of Individually Identifiable Health Information at
Page 340 - N/A
Page 341 - Employee and Labor Matters; Benefit Plans.
Page 342 - N/A
Page 343 - Environmental Matters. The Company is and since January 1, 2016 has complied with all applicable Env
Page 344 - Anti-Bribery. Neither the Company nor any of its directors, officers, employees or, to the Company s
Page 345 - Due Organization; Subsidiaries.
Page 346 - Non-Contravention; Consents. Subject to obtaining the Required Parent Stockholder Vote, the filing o
Page 347 - SEC Filings; Financial Statements.
Page 348 - Absence of Undisclosed Liabilities. As of the date hereof, Parent does not have any Liability, indiv
Page 349 - Intellectual Property.
Page 350 - Agreements, Contracts and Commitments. Section 3.11 of the Parent Disclosure Schedule identifies eac
Page 351 - Parent Material Contract ). There are no Parent Material Contracts that are not in written form. Par
Page 352 - Legal Proceedings; Orders.
Page 353 - Tax Matters.
Page 354 - Employee and Labor Matters; Benefit Plans.
Page 355 - N/A
Page 356 - Environmental Matters. Parent is and since January 1, 2016 has complied with all applicable Environm
Page 357 - Title to Assets. Parent owns, and has good and valid title to, or, in the case of leased properties
Page 358 - Disclaimer of Other Representations or Warranties. Except as previously set forth in this Section 3
Page 359 - Operation of the Company s Business.
Page 360 - N/A
Page 361 - Access and Investigation. Subject to the terms of the Confidentiality Agreement, which the Parties a
Page 362 - Company Non-Solicitation.
Page 363 - Notification of Certain Matters.
Page 364 - DLA ) and to Dechert LLP ( Dechert ) the applicable Tax Representation Letter referenced in Section
Page 365 - Stockholder Notice ) to every stockholder of the Company that did not execute the Company Stockholde
Page 366 - Parent Board Recommendation ); and (iii) the Parent Board Recommendation shall not be withheld, amen
Page 367 - Regulatory Approvals. Each Party shall use reasonable best efforts to file or otherwise submit, as s
Page 368 - Employee Benefits.
Page 369 - Additional Agreements. The Parties shall use commercially reasonable efforts to cause to be taken al
Page 370 - Listing. (a) Parent shall use its commercially reasonable efforts, to the extent required by the rul
Page 371 - Legends. Parent shall be entitled to place appropriate legends on the book entries and/or certificat
Page 372 - Allocation Certificate ); provided that the Company may update the Allocation Certificate by written
Page 373 - Calculation of Net Cash; Adjustment to Company and Parent Allocation Percentage.
Page 374 - Accounting Firm ) shall be engaged to resolve any remaining disagreements as to the determination of
Page 375 - Reverse Split ). Parent shall use commercially reasonable efforts, including engaging a proxy solici
Page 376 - Performance of Covenants. The Company shall have performed or complied with in all material respects
Page 377 - Performance of Covenants. Parent and Merger Sub shall have performed or complied with in all materia
Page 378 - N/A
Page 379 - Effect of Termination. In the event of the termination of this Agreement as provided in Section 9.1,
Page 380 - Non-Survival of Representations and Warranties. The representations and warranties of the Company, P
Page 381 - Attorneys Fees. In any action at law or suit in equity to enforce this Agreement or the rights of an
Page 382 - Cooperation. Each Party agrees to cooperate fully with the other Party and to execute and deliver su
Page 383 - N/A
Page 384 - IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above
Page 385 - IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above
Page 386 - EXHIBIT A
Page 387 - Company Capital Stock means the Company Common Stock and the Company Preferred Stock.
Page 388 - Company Net Cash Measurement Date means the Anticipated Closing Date; provided that if (i) the Closi
Page 389 - Contract means, with respect to any Person, any agreement, contract, subcontract, lease (whether for
Page 390 - GAAP means generally accepted accounting principles and practices in effect from time to time within
Page 391 - Governmental Authorization means any: (a) permit, license, certificate, franchise, permission, varia
Page 392 - Knowledge of Parent, Parent s Knowledge or similar terms means the actual knowledge of the individua
Page 393 - Parent Deficiency Amount means the amount equal to the minimum amount of the Parent Collar Range min
Page 394 - Parent Options means options or other rights to purchase shares of Parent Common Stock issued by Par
Page 395 - Permitted Encumbrance means: (a) any liens for current Taxes not yet due and payable or for Taxes th
Page 396 - Takeover Statute means any fair price, moratorium, control share acquisition or other similar anti-t
Page 397 - Treasury Regulations means the United States Treasury regulations promulgated under the Code.
Page 398 - N/A
Page 399 - Annex B
Page 400 - Annex C
Page 401 - Annex D
Page 402 - N/A
Page 403 - N/A
Page 404 - Annex E
Page 405 - N/A
Page 406 - N/A
Page 407 - N/A
Page 408 - PART II
Page 409 - N/A
Page 410 - N/A
Page 411 - N/A
Page 412 - N/A
Page 413 - N/A
Page 414 - N/A
Page 415 - N/A
Page 416 - SIGNATURES
Subdocument 2 - EX-10.19 - EXHIBIT 10.19
Page 1 - EMPLOYMENT AGREEMENT
Page 2 - dollar value of options by
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - No Unauthorized Competing Concern
Page 8 - Non-Solicitation of Employees
Page 9 - N/A
Page 10 - Affiliate
Page 11 - Applicable Period
Page 12 - Person
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - In Witness Whereof
Subdocument 3 - EX-10.20 - EXHIBIT 10.20
Page 1 - Exhibit 10.20
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Subdocument 4 - EX-10.21 - EXHIBIT 10.21
Page 1 - Exhibit 10.21
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Subdocument 5 - EX-10.22 - EXHIBIT 10.22
Page 1 - Exhibit 10.22
Page 2 - N/A
Page 3 - N/A
Page 4 - The above terms are accepted and approved:
Subdocument 6 - EX-10.23 - EXHIBIT 10.23
Page 1 - PDS BIOTECHNOLOGY CORPORATION
Page 2 - N/A
Page 3 - N/A
Page 4 - Signature page follows
Page 5 - N/A
Subdocument 7 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 8 - EX-23.2 - EXHIBIT 23.2
Page 1 - N/A
Subdocument 9 - EX-99.1 - EXHIBIT 99.1
Page 1 - Exhibit 99.1
Subdocument 10 - EX-99.3 - EXHIBIT 99.3
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts